spironolactone has been researched along with morphine in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (25.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 3 (18.75) | 29.6817 |
| 2010's | 8 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chu, H; Klemp, A; Stille, G | 1 |
| Gillette, JR; Stripp, B | 1 |
| Mécs, I; Savoie, L; Selye, H | 1 |
| Gazes, PC | 1 |
| Aouizerate, B; Barrot, M; Le Moal, M; Marinelli, M; Piazza, PV | 1 |
| Brown, L; Iyer, A; Mesripour, A | 1 |
| Jokinen, V; Kalso, EA; Lilius, TO; Neuvonen, MS; Niemi, M; Rauhala, PV; Väänänen, AJ | 1 |
| Laorden, ML; Milanés, MV; Navarro-Zaragoza, J | 2 |
| Jokinen, V; Kalso, E; Kambur, O; Laitila, J; Lilius, T; Niemi, M; Rauhala, P | 1 |
1 review(s) available for spironolactone and morphine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
15 other study(ies) available for spironolactone and morphine
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Effects of furosemide and spironolactone on the behavior of morphine-tolerant rats.
Topics: Animals; Behavior, Animal; Catalepsy; Drug Tolerance; Female; Furosemide; Humans; Lethal Dose 50; Morphine; Rats; Spironolactone; Stereotyped Behavior; Time Factors | 1978 |
Role of drug metabolism in drug research and development: factors affecting metabolism of drugs and their pharmacological and toxicological activity.
Topics: Animals; Benzene Derivatives; Benzopyrenes; Cortisone; Cytochrome c Group; Cytochrome P-450 Enzyme System; Dealkylation; Diazepam; Female; Guinea Pigs; Hexobarbital; Hydroxylation; Male; Methylcholanthrene; Mice; Microsomes, Liver; Morphine; Oxidoreductases; Pentylenetetrazole; Pharmaceutical Preparations; Phenobarbital; Rats; Research; Sleep; Spironolactone | 1972 |
Inhibition of anesthetics and sedative actions by spironolactone.
Topics: Anesthetics; Animals; Bromides; Chloral Hydrate; Chlorides; Chlorpromazine; Dehydroepiandrosterone; Desoxycorticosterone; Diazepam; Diethylstilbestrol; Ethanol; Female; Hypnotics and Sedatives; Magnesium; Morphine; Pentobarbital; Phenoxybenzamine; Potassium; Pregnanediones; Pregnanes; Progesterone; Rats; Reserpine; Sodium; Spironolactone; Testosterone | 1969 |
Treatment of heart failure. 2.
Topics: Acetazolamide; Diuretics; Ethacrynic Acid; Furosemide; Heart Failure; Humans; Morphine; Pulmonary Edema; Spironolactone; Triamterene | 1972 |
Dopamine-dependent responses to morphine depend on glucocorticoid receptors.
Topics: Animals; Dopamine; Hormone Antagonists; Male; Mifepristone; Mineralocorticoid Receptor Antagonists; Morphine; Motor Activity; Narcotics; Nucleus Accumbens; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Spironolactone | 1998 |
Mineralocorticoid receptors mediate cardiac remodelling in morphine-dependent rats.
Topics: Animals; Blood Pressure; Cardiomegaly; Dose-Response Relationship, Drug; Heart; Heart Ventricles; In Vitro Techniques; Male; Malondialdehyde; Microscopy, Confocal; Mineralocorticoid Receptor Antagonists; Morphine; Organ Size; Rats; Rats, Wistar; Receptors, Mineralocorticoid; Spironolactone; Ventricular Remodeling | 2012 |
The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception.
Topics: Analgesics; Animals; Drug Interactions; Male; Mineralocorticoid Receptor Antagonists; Morphine; Pain; Pain Measurement; Rats; Rats, Sprague-Dawley; Spironolactone; Tissue Distribution | 2014 |
Spironolactone decreases the somatic signs of opiate withdrawal by blocking the mineralocorticoid receptors (MR).
Topics: Analgesics, Opioid; Animals; Disease Models, Animal; Enzyme Activation; Hypothalamo-Hypophyseal System; Hypothalamus; Male; Mineralocorticoid Receptor Antagonists; Morphine; Naloxone; Narcotic Antagonists; Norepinephrine; Opioid-Related Disorders; Paraventricular Hypothalamic Nucleus; Phosphorylation; Pituitary-Adrenal System; Proto-Oncogene Proteins c-fos; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Signal Transduction; Spironolactone; Substance Withdrawal Syndrome; Tyrosine 3-Monooxygenase | 2014 |
Glucocorticoid receptor but not mineralocorticoid receptor mediates the activation of ERK pathway and CREB during morphine withdrawal.
Topics: Analgesics, Opioid; Animals; Cyclic AMP Response Element-Binding Protein; Dopamine; Hormone Antagonists; Male; MAP Kinase Signaling System; Mifepristone; Mineralocorticoid Receptor Antagonists; Morphine; Naloxone; Narcotic Antagonists; Nucleus Accumbens; Phosphorylation; Rats; Rats, Sprague-Dawley; Receptors, Glucocorticoid; Receptors, Mineralocorticoid; Spironolactone; Substance Withdrawal Syndrome; Tyrosine 3-Monooxygenase | 2017 |
Do Diuretics have Antinociceptive Actions: Studies of Spironolactone, Eplerenone, Furosemide and Chlorothiazide, Individually and with Oxycodone and Morphine.
Topics: Analgesics; Analgesics, Opioid; Animals; Behavior, Animal; Brain; Chlorothiazide; Disease Models, Animal; Diuretics; Drug Interactions; Drug Therapy, Combination; Eplerenone; Furosemide; Male; Morphine; Neurons; Oxycodone; Pain; Rats, Sprague-Dawley; Spironolactone; Tissue Distribution | 2017 |